medicines for africa (mfa)’s Post

In an exclusive interview with Global Business Report (GBR), Subodh Deshmukh, CEO of Biologics and President of Development, along with Ramesh Subramanian, CCO of Aragen Life Sciences, share insights about the growth of biologics in the USA and key insights on why automation is important in the CDMO and CRO segments in the current scenario. Click on the link below to get complete insight into the current dynamics of the CDMO and CRO industry. #interview #cdmo #cro #drugdevelopment #biologics #usa #lifesciencesupdates #markettrends #exclusive

SFBN Feed: What happens when an approved drug doesn’t work? https://lnkd.in/g2F5whPe Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey there. Today, we see the first approval of a drug to treat MASH, [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

As the CMO of Legend Biotech, Mythili Koneru, MD, explains how she is approaching her role. Learn more about what her primary focuses are and her tips and insights on being a first time CMO in our interview with her below. Read the article here: https://lnkd.in/e8JepAtj #BioTech #CMO #ChiefMedicalOfficer

Thanks to everyone who joined and asked questions at our seminar with N=1 Collaborative yesterday! Our Chief Technology Officer, David Butler, spoke on a panel of experts about "Control of regulatory starting material quality for oligonucleotide therapeutics". During the talk, David provided insights into the synthesis of phosphoramidites, a systematic approach to categorizing phosphoramidite impurities, and analytical techniques for purity and impurities characterization and measurement of amidites used in N=1 oligonucleotides. Did you miss it? Don't worry, you can catch up with the recording on-demand via the link below. 👇 https://loom.ly/4n4G4Kw #Oligonucleotides #PharmaEvent #CDMO

#Biotechnology contract manufacturing has witnessed exponential growth, now an integral component of the global biotech ecosystem. Priyanka Bhendale of MarketsandMarkets™ takes a deeper look. #contractmanufacturing #biosimilars

Did you hear that we recently acquired AbCheck s.r.o.? Learn more about the acquisition and how it boosts our Address, Navigate, Determine (AND)™ Platform and enhances our ability to generate multiple AND-Body™ Therapeutics in parallel: https://bit.ly/47AA18g #Biotechnology #Healthcare #DrugDiscovery #DrugDevelopment

📢Gilead Sciences Ditches Oceanside Expansion for Foster City ⭐ Gilead Sciences has cancelled its plans to expand its Oceanside facility and will instead move biologics production to Foster City. ⭐ #BioprocessUpdates #GileadSciences #OceansideExpansionCancelled #BiologicsProduction #FosterCity #PharmaceuticalIndustry #HealthcareNews #DrugDevelopment #ResearchAndDevelopment #Biotechnology #Medicine #Science #BusinessNews #CompanyUpdate #GileadMoves #FacilityExpansion ▷ Read the full article here: 📎 https://lnkd.in/dDuGhSbF

𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗟𝗶𝗰𝗲𝗻𝘀𝗲 𝗳𝗼𝗿 𝗖𝗛𝗢𝗞𝟭𝗕𝗡 Biointron's CHOK1BN cell line, sourced from ECACC and adapted explicitly for suspension culture in essential CD media, is valuable for antibody-related research. It is fully traceable from the original CHO cell line and can be sublicensed for commercial use. It's compliant with registration requirements in both China and the United States, making it a reliable and accessible choice for antibody development and production. In addition, the license is perpetual and irrevocable, only requiring a one-time sublicence fee.   Read more here: https://lnkd.in/d4JSMtsJ #Biointron #Antibodies #Protein #DrugDevelopment #StableCellLine #CHOCells

High correct bispecific chain pairing. See how we address production efficiency and cost of goods reduction from the outset for the development of bispecifics.

📢 Attention biotech innovators and investors! Please read Dr. Sandra Ragaz-Fumia's and Dominik H.'s latest blog, “Trustworthy Biotech Ventures: Building Investor Confidence with Regulatory Strategies”, is now live! This guide offers insights into regulatory strategies and building investor trust. 🧬 Highlights: • US and EU market authorisation processes • Strategies for transparent investor relationships • Key regulatory milestones for business success Stay informed and read the full article https://lnkd.in/eDQiD8MU. Navigate the regulatory landscape and achieve long-term success! #Pharma #Biotech #RegulatoryAffairs #InvestorRelations #PwC #LifeSciences #Innovation